453 related articles for article (PubMed ID: 32982179)
1. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
2. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
[TBL] [Abstract][Full Text] [Related]
3. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
5. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
[TBL] [Abstract][Full Text] [Related]
6. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
7. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
8. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
Muszbek N; Remak E; Xin Q; McNamara L; Jones T
J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
[No Abstract] [Full Text] [Related]
12. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
[TBL] [Abstract][Full Text] [Related]
13. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
Afifi S; Mohamed S; Zhao J; Foss F
Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
[No Abstract] [Full Text] [Related]
14. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
[No Abstract] [Full Text] [Related]
15. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
16. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
[TBL] [Abstract][Full Text] [Related]
17. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
[TBL] [Abstract][Full Text] [Related]
18. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
Mukai M; Mould D; Maeda H; Narushima K; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
[TBL] [Abstract][Full Text] [Related]
19. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.
Johnson WT; Kartan S; Sokol K; Nikbakht N; Porcu P
Leuk Lymphoma; 2021 Aug; 62(8):1877-1883. PubMed ID: 33618592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]